A RETROSPECTIVE COMPARATIVE STUDY OF TOXICITIES AND OUTCOMES BETWEEN GEMCITABINE + NAB PACLITAXEL AND FOLFIRINOX IN LOCALLY ADVANCED CA PANCREAS RECEIVING IN NEO-ADJUVANT CHEMOTHERAPY

Neoadjuvant chemotherapy with Gemcitabine/nab-paclitaxel (Gemcitabine + Nab-Paclitaxel) And Folfirinox (Folfirinox) are two standard therapies for patients who has locally advanced pancreatic cancer (Lapc). We retrospectively compared the efficacy and safety of the two treatment regimens in patients with unresectable pancreatic cancer. The sample size consisted of 96 patients who has locally advanced pancreatic cancer. (Gnp) Gemcitabine and nab–paclitaxel is Group I (N=53), and Folfirinox consisting of leucovorin, fluorouracil, irinotecan and oxaliplatin is Group II (N=43). The Primary objectives of our study were to compare toxicities between gemcitabine + Nab-Paclitaxel And Folfirinox and to evaluate the safety of these regimens The secondary objective was % reduction of tumor, Surgery (% of patients who underwent surgery) and overall survival both estimated using the independent t- test and chi-square test. Results: The haematological toxicities rates were similar between the two groups (62% vs. 63%; p > 0.05), with similar anemia toxicities rates (62%). The neutropenia toxicity rates were similar (15% vs 16%; p>0.05) and febrile neutropenia, thrombocytopenia, and GI toxicities were higher in group II than group I. In analysis % reduction of tumor was similar between both groups with a P value of 0.3510, calculated by dependent t – test. Patients who underwent surgery were slightly more in Group I.